Drug Trial Radar · NCT00534183
Metabolic Profile and Anthropometric Changes in Schizophrenia
Last checked: Nov 19, 2026Latest source record: Sep 24, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,006
Actual
Start
Jun 2006
Primary completion
Not stated
Study completion Dec 2006
Sponsor
- Lead sponsor
- Central Institute of Psychiatry, Ranchi, IndiaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 24, 2007
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Screening
- Who can join
- All sexes, from 18 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
"No clinical differences will be found between the three antipsychotics under study - olanzapine, risperidone and haloperidol - on the patients' metabolic profile and weight. "
Conditions
- Metabolic Syndrome
- Diabetes
- Obesity
Interventions
OlanzapineDrug
Olanzapine in dose range of 10-20mg
RisperidoneDrug
Risperidone 1-6mg
HaloperidolDrug
Haloperidol 10-20mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Study of metabolic profileTime frame: 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Central Institute of Psychiatry
Ranchi, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.